• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 92
  • 81
  • 8
  • 7
  • 6
  • 5
  • 4
  • 3
  • 3
  • 3
  • 2
  • 2
  • 2
  • 1
  • Tagged with
  • 243
  • 80
  • 40
  • 36
  • 26
  • 24
  • 21
  • 21
  • 21
  • 17
  • 17
  • 17
  • 16
  • 16
  • 16
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
211

Antitumor Activities of 2-Methoxyestradiol on Cervical and Endometrial Cancers In Vitro and In Vivo

Li, Li January 2004 (has links)
<p>2-Methoxyestradiol (2-ME), a metabolite of 17β-estradiol, is a potent antitumor and antiangiogenesis agent in vitro and in vivo. This study aimed to investigate the effects of 2-ME on human cervical and endometrial cancers in vitro and in vivo. Human cervical cancer HeLaS3 cells, endometrial cancer HEC-1-A and RL-95-2 cells, and severe combined immune deficient (SCID) mice were used. On cervical cancer HeLaS3 cells, 2-ME inhibited the cell growth which is accompanied by apoptosis via iNOS pathway and by G<sub>2</sub>/M cell cycle arrest. 2-ME had slight effects on normal cervical epithelial cells. In vivo on SCID mice, 2-ME (75 mg/kg p.o.) inhibited the growth of human cervical carcinoma by 34% (p < 0.05) and showed slight side effects to liver and spleen. On human endometrial cancer cells (HEC-1-A and RL-95-2 cells), 2-ME inhibited the growth by blocking cell cycle progress in S- and G<sub>2</sub>/M-phase in both cell types, and by inducing apoptosis in HEC-1-A cells and by causing necrosis in RL-95-2 cells. 2-ME had no effects on normal endometrial cells. The apoptotic effect, in HEC-1-A cells, was prevented by iNOS-inhibitor 1400W and eliminated by Caspase-inhibitor Z-VAD-FMK. The necrosis, on RL-95-2 cells, was due to a severe disruption of the mitochondrial membrane potential. Unfortunately, 2-ME had no significant effects on endometrial cancer xenografts. It showed slight toxicity to liver, spleen and proliferative effect on uterus. In conclusion, 2-ME inhibits the growth of human cervical and endometrial cancer cells in vitro. However, a weaker anti-tumor effect was observed in our animal model and 2-ME was slightly toxic to liver and spleen. Considering the proliferative effect on uterus, 2-ME might not be a suitable therapeutic agent in gynecological tumors.</p>
212

Methods for Analysis of Disease Associated Genomic Sequence Variation

Lovmar, Lovisa January 2004 (has links)
In Molecular Medicine a wide range of methods are applied to analyze the genome to find genetic predictors of human disease. Apart from predisposing disease, genetic variations may also serve as genetic markers in the search for factors underlying complex diseases. Additionally, they provide a means to distinguish between species, analyze evolutionary relationships and subdivide species into strains. The development and improvement of laboratory techniques and computational methods was a spin-off effect of the Human Genome Project. The same techniques for analyzing genomic sequence variations may be used independent of organism or source of DNA or RNA. In this thesis, methods for high-throughput analysis of sequence variations were developed, evaluated and applied. The performance of several genotyping assays were investigated prior to genotyping 4000 samples in a co-operative genetic epidemiological study. Sequence variations in the estrogen receptor alpha gene were found to be associated with an increased risk of breast and endometrial cancer in Swedish women. Whole genome amplification (WGA) enables large scale genetic analysis of sparse amounts of biobanked DNA samples. The performance of two WGA methods was evaluated using four-color minisequencing on tag-arrays. Our in-house developed assay and “array of arrays” format allow up to 80 samples to be analyzed in parallel on a single microscope slide. Multiple displacement amplification by the Φ29 DNA polymerase gave essentially identical genotyping results as genomic DNA. To facilitate accurate method comparisons, a cluster quality assessment approach was established and applied to assess the performance of four commercially available DNA polymerases in the tag-array minisequencing assay. A microarray method for genotyping human group A rotavirus (HRV) was developed and applied to an epidemiological survey of infectious HRV strains in Nicaragua. The method combines specific capture of amplified viral sequences on microarrays with genotype-specific DNA-polymerase mediated extension of capture oligonucleotides with fluorescent dNTPs.
213

Apoptosis, proliferation, and sex steroid receptors in endometrium and endometrial carcinoma

Dahmoun, Marju January 2003 (has links)
This thesis focuses on the involvement of apoptosis and proliferation in the mechanisms of menstruation and hormonal replacement therapy, HRT, as well as in the mechanisms of progesterone therapy in endometrial carcinoma. The aim of the first study was to investigate endometrium for 4 days before and for 2 days during menstruation. In the epithelium, rapid increase in the apoptotic index, decreasing expression of estrogen receptor α (ER) and progesterone receptor (PR), and minimal proliferation were observed prior to menstruation. In the stroma, an increase in the expression of ER and PR and proliferation was seen before the final decrease, and increased apoptosis was seen during menstruation. Thus, apoptosis is involved in the remodeling of the endometrium during menstruation. Postmenopausal endometrium showed unaffected homeostasis, i.e. unchanged ratio between apoptotic index and Ki-67 index during substitution therapy. ER expression was decreased both in the epithelium and stroma, while PR showed some increase in receptor expression. The unchanged homeostasis contributes to endometrial safety during combined continuous HRT. Unchanged apoptosis and increasing proliferation were observed with increasing tumor grade in 29 patients with endometrioid endometrial carcinoma, which may contribute to greater aggression as tumor grade increases. Decreased proliferation was observed after medroxy-progesterone at 20 mg per day particularly in the foci of maximal proliferation in G1 and G2 tumors. The expression of ER was unchanged, while PR was decreased in the foci of maximal expression for PR in G1 and G2 tumors. Since high proliferation and PR expression also coexisted in the same foci, evaluated in G1 and G2 tumors, the effect of progesterone could be facilitated in these tumor groups. High expression of sex steroid receptors was also a predicting factor for good response to progesterone (= decrease in proliferation), while the amount of stroma could not predict that effect.
214

Genetic and epidemiological studies of hereditary colorectal cancer

Cederquist, Kristina January 2005 (has links)
Lynch syndrome (Hereditary Nonpolyposis Colorectal Cancer, HNPCC) is the most common hereditary syndrome predisposing to colorectal cancer, accounting for 1-3% of all colorectal cancer. This multi-organ cancer predisposition syndrome is caused by mutations in the mismatch repair (MMR) genes, especially MLH1 and MSH2, and to lesser extents MSH6 and PMS2, which lead to widespread genetic instability and thus microsatellite instability (MSI). Hereditary cancer often manifests in two or more tumours in a single individual; 35-40% of Lynch syndrome patients have synchronous or metachronous tumours of the two major Lynch syndrome-related cancers: colorectal and endometrial. The main purposes of the work underlying this thesis were to identify persons at risk of Lynch syndrome or other types of hereditary colorectal cancer, to estimate the cancer risks associated with these predispositions and to identify the underlying genetic causes. A population-based cohort of 78 persons with double primary colorectal or colorectal and endometrial cancer was identified. Cancer risks in their 649 first-degree relatives were estimated in relation to tumour MSI status (positive or negative) and age at diagnosis (before or after 50 years of age) in the probands. The overall standardised incidence ratio was 1.69 (95% CI; 1.39-2.03). The highest risks for Lynch syndrome-associated cancers: (colorectal, endometrial, ovarian and gastric) were found in families with young MSI-positive probands, likely representing Lynch syndrome families. Importantly, no overall risk was found in families with old probands, irrespective of MSI status. Blood samples were available from 24 MSI-positive patients for mutation screening of MLH1, MSH2 and MSH6. Sequence variants or rearrangements predicted to affect protein function were found in 16 patients. Six novel variants were found: two large rearrangements, two truncating and two missense mutations. The missense mutations were found to segregate in the families. Studies of allele frequencies, MSI and loss of immunostaning in tumours from family members further supports the hypothesis that these missense changes play a role in Lynch syndrome, as do the non-conservative nature and evolutionary conservation of the amino acid exchanges. Five families had mutations in MLH1, five in MSH2, and six in MSH6. The unexpectedly large impact of MSH6 was in genealogical studies shown to be due to a founder effect. Cumulative risk studies showed that the MSH6 families, despite their late age of onset, have a high lifetime risk for all Lynch syndrome-related cancers, significantly higher in women (89% by age 80 years) than in men (69%). The gender differences are in part due to high endometrial (70%) and ovarian cancer risk (33%) in addition to the high colorectal cancer risk (60%). These findings are of great importance for counselling and surveillance of families with MSH6 mutations. Finally, in a large family with MSI-negative hereditary colorectal cancer for which the MMR genes and APC had been excluded as possible causes, a genome-wide linkage analysis was performed, resulting in a suggested linkage to chromosome 7. Conclusions: Relatives of probands with MSI-positive, double primary colorectal and endometrial cancer diagnosed before the age of 50 years have significantly increased risks of Lynch syndrome-related cancers. MSH6 mutations, which have unusually high impact in this study population due to a founder effect, confer high cumulative risks of cancer despite the generally late age of onset.
215

Antitumor Activities of 2-Methoxyestradiol on Cervical and Endometrial Cancers In Vitro and In Vivo

Li, Li January 2004 (has links)
2-Methoxyestradiol (2-ME), a metabolite of 17β-estradiol, is a potent antitumor and antiangiogenesis agent in vitro and in vivo. This study aimed to investigate the effects of 2-ME on human cervical and endometrial cancers in vitro and in vivo. Human cervical cancer HeLaS3 cells, endometrial cancer HEC-1-A and RL-95-2 cells, and severe combined immune deficient (SCID) mice were used. On cervical cancer HeLaS3 cells, 2-ME inhibited the cell growth which is accompanied by apoptosis via iNOS pathway and by G2/M cell cycle arrest. 2-ME had slight effects on normal cervical epithelial cells. In vivo on SCID mice, 2-ME (75 mg/kg p.o.) inhibited the growth of human cervical carcinoma by 34% (p &lt; 0.05) and showed slight side effects to liver and spleen. On human endometrial cancer cells (HEC-1-A and RL-95-2 cells), 2-ME inhibited the growth by blocking cell cycle progress in S- and G2/M-phase in both cell types, and by inducing apoptosis in HEC-1-A cells and by causing necrosis in RL-95-2 cells. 2-ME had no effects on normal endometrial cells. The apoptotic effect, in HEC-1-A cells, was prevented by iNOS-inhibitor 1400W and eliminated by Caspase-inhibitor Z-VAD-FMK. The necrosis, on RL-95-2 cells, was due to a severe disruption of the mitochondrial membrane potential. Unfortunately, 2-ME had no significant effects on endometrial cancer xenografts. It showed slight toxicity to liver, spleen and proliferative effect on uterus. In conclusion, 2-ME inhibits the growth of human cervical and endometrial cancer cells in vitro. However, a weaker anti-tumor effect was observed in our animal model and 2-ME was slightly toxic to liver and spleen. Considering the proliferative effect on uterus, 2-ME might not be a suitable therapeutic agent in gynecological tumors.
216

Präklinische Evaluation: Glykolyseinhibition in Kombination mit GnRH-Rezeptor-vermittelter Therapie zur Behandlung gynäkologischer Karzinome / Preclinical Evaluation: Inhibition of Glycolysis in Combination with GnRH Receptor Targeted Therapy for Treatment of Gynecological Carcinomas

Reutter, Madita Dora 12 July 2011 (has links)
No description available.
217

Comparison of a leukocyte esterase test with endometrial cytology for the diagnosis of subclinical endometritis and correlation with first service pregnancy rate in postpartum Holstein cows

Couto, Gabriel B. 11 1900 (has links)
L’objectif de la présente étude était d’évaluer un test d’estérase leucocytaire (LE) pour le diagnostic de l’endométrite subclinique chez les vaches Holstein en période postpartum. Les tests effectués à partir d’échantillons provenant soit de l’endomètre (UtLE) ou du col utérin (CxLE) ont été comparés à la cytologie endométriale (CE). Par ailleurs, deux méthodes d’évaluation des lames ont été comparées. Deux cent quatre vingt-cinq vaches Holstein de 5 troupeaux laitiers commerciaux ont été évaluées entre 21 et 47 jours en lait (JEL). Soixante sept vaches ont été diagnostiquées avec une endométrite clinique suite à un examen transrectal et vaginoscopique et ont été exclues de l’étude. Deux cent dix-huit vaches ont eu des prélèvements pour la CE et le test LE. La fonction ovarienne a été déterminée à la palpation transrectale. La banque de données utilisée pour chacune des vaches a été effectuée à partir du logiciel DSA (Dossier de Santé Animale) laitier. Le pourcentage de neutrophiles était significativement corrélé avec les scores de LE utérin et cervical. L’activité de CxLE et UtLE diminuait significativement avec les JEL, mais n’était pas associée au risque de gestation à 90 JEL (n= 186). Le pourcentage de neutrophiles mesuré à la CE entre 32 et 47 JEL était associé significativement au risque de gestation à 90 JEL (n=94, P=0.04). Pour la même période, selon une analyse de survie, les vaches avec >2,6% de neutrophiles à la CE étaient définies comme étant atteintes d’une endométrite subclinique avec une prévalence de 56%. Les résultats indiquent que le test d’estérase utérin ou cervical a une bonne concordance avec le pourcentage de neutrophiles à la CE. Une endométrite subclinique diagnostiquée par cytologie endometriale entre 32 et 47 JEL est associée à une réduction du risque de gestation au premier service. / The point toward this study was to determine the diagnostic test characteristics of the leukocyte esterase activity test for subclinical endometritis in postpartum Holstein dairy cows. The objectives were 1) to compare uterine leukocyte esterase activity and the endometrial cytology (EC), 2) to compare leukocyte esterase activity of the cervix (CxLE) and the uterus (UtLE), 3) Compare two methods of assessing the slides (i.e. an exhaustive method and a rapid method). Two hundred eighty five post partum Holstein cows from 5 commercial dairy herds had a post partum evaluation between 21 and 47 days in milk (DIM). Sixty seven cows where diagnosed with clinical endometritis by transrectal and vaginoscopy examinations and were excluded from the study. Two hundred eighteen cows were enrolled for endometrial cytology and esterase activity test. The ovarian status was determined by transrectal examination. Computerized databank, dairy DSA (Dossier de Santé Animale) indexing all the cows was used to retrieve individual information for analysis. The percentage of neutrophils was significantly correlated with the LE from the uterus and cervix. The LE from cervix and uterus decreased significantly with DIM, however, they were not statistically associated with pregnancy risk at 90 DIM (n=186). Between 32-47 DIM, the percentage of neutrophils and risk of pregnancy at 90 DIM were associated (n=94, P=0.04). For the same period, survival analysis identified cows with > 2.6 % neutrophils on EC as subclinical endometritis cows with a prevalence of 56%. The two methods for assessing the slides were correlated by 81%. Subclinical endometritis diagnosed by endometrial cytology between 32 and 47 DIM was associated with reduced risk of pregnancy at first service.
218

Efeito do tratamento com metformina sobre o desenvolvimento, potencial metastásico e vias de sinalização do câncer de endométrio in vitro

Machado, Amanda de Barros January 2017 (has links)
Endometriumkrebs ist eine der häufigsten gynäkologischen Malignomen weltweit und wird in einen Typ I eingeteilt, welcher östrogenabhängig ist, und in eine Typ-II-Östrogen-unabhängige Form. Typ I ist der häufigste Fall und kommt in etwa für 75% bis 85% aller diagnostizierten Fälle in Frage. Erhöhte Östrogenspiegel haben gezeigt, das Risiko von Gebärmutterkrebsentwicklung zu erhöhen, genauso wie Östrogen die Proliferation von Endometriumzellen stimuliert und die Apoptose hemmt. Die Insulinresistenz scheint eine zentrale Rolle in der endometrialen Karzinogenese zu spielen und darüber hinaus werden Erkrankungen mit Insulinresistenz, wie zum Beispiel das polyzystische Ovarialsyndrom (PCOS) und Adipositas, sowie Typ II-Diabetes mellitus (DM) als signifikantes Risiko angesehen, Faktoren für die Entwicklung und Progression von Typ-I-Endometrium-Krebs zu sein. Zusätzlich können PCOS-Patienten durch eine Fettleibigkeit in einem normoglykämischen Status eine unabhängige Insulin-Resistenz haben. In diesem Fall scheint die Hyperinsulinämie der fördernde Faktor zu sein, nicht nur für die Entwicklung als auch für die Tumorprogression.Aber auch erhöhte Blutzuckerspiegel tragen zum Wachstum und die Karzinogenese in Endometriumkarzinom bei und dienen als wichtige Verbindung zwischen dem beobachteten erhöhten Krebsrisiko bei Patienten mit Typ-II-DM. Die Behandlung mit einem Anti-Diabetikum, welches den Insulinspiegel senken kann, könnte einen allgemeinen Ansatz bieten gegen die Entwicklung von Krebs und zur Verringerung der Metastasierung. Das Ziel dieser Studie war es, die Wirkung einer 0,1 mM Metformin-Dosis auf das proliferative und metastatische Potential von Endometriumkrebszellen bewerten zu können, sowie die Analyse der Auswirkungen von kurz- und langfristigen Behandlungen auf intrazelluläre Signalwege der Endometriumkrebszellen.(Fortsetzung) (Fortsetzung)Ebenso soll der Zusammenhang der Entwicklung und der Progression von Krebszellen untersucht werden, wenn sie einer Umgebung mit unterschiedlichen Glucosekonzentrationen und hohen Insulinspiegeln ausgesetzt werden. Darüber hinaus ist eine endometriale dreidimensionale (3D) Cokultur zu standardisieren, für eine viabele Kultur bei 20 Tagen Kultivierung. Das proliferative Potential wurde unter Verwendung des CellTitle-Glo-Tests durchgeführt, und das metastatische Potential wurde unter Verwendung von Transwell-Migration und Invasion untersucht. Die mRNAExpression von MKI67, mTOR, NOTCH1, NOTCH3 und JAG1 Gene wurden durch real-time PCR gemessen. Die kumulative Populationsverdopplungsrate wurde durch das Replikationsverhalten einer Endometriumkrebszelllinie durchgehend von 20 Tagen nach einer Behandlungsdauer bestimmt. In allen Assays wurden die Zellen durch Medien mit normaler (5,5 mM) oder hoher (17 mM) Glucosekonzentration, sowie in verschiedenen Gruppen behandelt: Kontrolle, Insulin, Metformin und Insulin+Metformin. Das 3D-Kokulturmodell wurde unter Verwendung von endometrialen Primärzellen und einer Endometriumkrebszelllinie hergestellt, wobei die Modellkonstruktion durch Matrigel® als extrazelluläre Matrix verwendet wurde. In dieser Studie hemmte die 0,1 mM Metformin-Dosis die Insulinwirkung stark und verringerte die Fähigkeit der endometrialen Krebszelllinie, in einer hohen und normalen Glukoseumgebung zu migrieren und einzudringen.(Fortsetzung) (Fortsetzung) Auf das proliferative Potential wurde dieser Effekt nicht beobachtet, allerdings reagierte die relative Zellproliferation empfindlich auf Metformin im Bereich zwischen 1 und 5 mM, unabhängig von der vorliegenden Glucosekonzentration. In den intrazellulären molekularen Mechanismen wurde beobachtet, dass die hohe Glukosekonzentration eine optimale Umgebung für endometriale Krebszellen schafft, um einen aggressiveren Genotyp und eine Resistenz gegenüber Metformin während einer Langzeitbehandlung zu zeigen. Darüber hinaus blieb das endometriale 3DKokulturmodell über 20 Kulturtage lebensfähig. Daher zeigte sich, trotz der Endometriumkrebszellen, eine Resistenz gegenüber dem Metformin-Effekt, wenn sie einer hohen Glucoseumgebung ausgesetzt waren. Die 0,1 mM Metformin-Dosis war in der Lage, die Insulinwirkung zu hemmen und das metastatische Potential der Zellen zu verringern, was darauf hindeutet, dass Metformin klinisch in Verbindung mit Insulin wirkt, sowie die indirekten und direkten Effekte als potentieller Wirkstoff in der Krebstherapie eingesetzt werden könnten. / O câncer de endométrio é uma das neoplasias ginecológicas com maior incidência, classificado como tipo I, estrógeno dependente, e tipo II, estrógeno nãodependente. O tipo I é a forma mais comum, ocorrendo em torno de 75 – 85 % dos casos de câncer de endométrio. Altos níveis de estrogênio têm sido relacionados ao aumento do risco de desenvolvimento do câncer de endométrio, pois estimula a proliferação celular e inibe a apoptose. A resistência à insulina parece desempenhar um papel central nesta neoplasia, e as doenças associadas à resistência à insulina como obesidade, Diabetes Mellitus (DM) tipo II e Síndrome dos Ovários Policísticos (PCOS) também são consideradas fatores de risco significantes para o desenvolvimento e progressão do câncer de endométrio tipo I. Adicionalmente, pacientes com PCOS podem apresentar um quadro de resistência à insulina independente de obesidade, permanecendo em um estado glicêmico normal. Neste caso, a hiperinsulinemia isolada seria um fator tanto para a promoção, como também para a progressão do câncer. Entretanto, o aumento de níveis séricos de glicose, a hiperglicemia, também é considerada um fator independente para o desenvolvimento e progressão do câncer de endométrio sendo um elo crítico entre o aumento do risco do desenvolvimento de câncer observado em pacientes com DM tipo II Dessa forma, tratamento utilizando agentes insulino-sensibilizantes, que atuam diminuindo a resistência à insulina e consequentemente reduzindo seus níveis pode ser uma estratégia interessante para prevenir o câncer e reduzir a disseminação metastática. Os objetivos deste trabalho foram avaliar o efeito da dose de 0,1 mM de metformina sobre o potencial proliferativo e metastático das células de câncer de endométrio, assim como, avaliar o efeito do tratamento a curto e a longo prazo sobre vias de sinalização intracelular relacionadas ao desenvolvimento e progressão do câncer de endométrio quando exposta a um ambiente com diferentes concentrações de glicose e níveis elevados de insulina. Por fim, a padronização de um modelo tridimensional (3D) de cocultura de células de endométrio que permanecesse viável ao longo de 20 dias de cultivo. O potencial proliferativo foi determinado pelo método luminescente CellTitle Glo, e o potencial metastático pelo o ensaio transwell de migração e invasão. Análises de expressão do mRNA dos genes MKI67, mTOR, NOTCH1, NOTCH3 e JAG1 foram realizadas a partir da técnica de PCR em tempo real. O índice de duplicação populacional cumulativo das células determinou o comportamento de replicação da linhagem de câncer de endométrio ao longo do período de tratamento de 20 dias. Em todas os ensaios as células foram cultivadas em meio contendo concentrações normais (5,5 mM) ou altas (17 mM) de glicose, e divididas nos diferentes grupos de tratamento: controle, insulina, metformina e metformina associado a insulina. A padronização do modelo 3D de cocultura de células de endométrio foi realizado utilizando células primárias e células de linhagem de câncer de endométrio, a Matrigel® foi a matriz extracelular temporária utilizada para a construção do modelo. Neste estudo, a concentração de 0,1 mM de metformina inibiu a ação da insulina, diminuindo a habilidade de migração e invasão das células de câncer de endométrio independente da concentração de glicose presente no meio. Entretanto, este efeito não foi observado sobre o potencial proliferativo, sendo observada uma redução da proliferação das células de câncer de endométrio ao serem utilizadas concentrações maiores de metformina. Em relação aos mecanismos moleculares intracelulares, foi observado que na presença de altas concentrações de glicose as células de câncer de endométrio adquirem um genótipo mais agressivo e apresentam resistência ao efeito da metformina na dose de 0,1 mM durante o tratamento agudo. Além disso, foi possível a padronização de um modelo 3D de cocultura de células de câncer de endométrio que permanecesse viável ao longo dos 20 dias de cultivo. Contudo, apesar das células de câncer de endométrio apresentarem resistência ao efeito da metformina na presença de altas concentrações de glicose, a dose de 0,1 mM foi capaz de inibir o efeito da insulina e diminuir o potencial metastático dessas células, sugerindo que a metformina ao atuar clinicamente em combinação com seus efeitos indiretos e diretos pode ser um potencial agente adjuvante na terapia contra o câncer. / Endometrial cancer is one of the most common gynecological malignancies worldwide and is classified into a type I, which is estrogen-dependent, and a type II estrogen-independent form. The type I is the most common, accounting to 75%-85% of all cases of endometrial cancer. Elevated estrogen levels have been shown to increase the risk of endometrial cancer development, as estrogen stimulates endometrial cell proliferation and inhibits apoptosis. The insulin resistance seems to play a central role in endometrial carcinogenesis, furthermore, diseases associate with insulin resistance, as seen in polycystic ovary syndrome (PCOS), and obesity, as well as type II diabetes mellitus (DM) are considered as significant risk factors for the development and progression of type I endometrial cancer. Additionally, PCOS patients may have an insulin resistance independent of obesity remaining in a normoglycemic status. At this case, the hypeinsulinemia seems to be the promoter factor not only for the development but also for the cancer progression. However, also increased blood glucose levels are contributing to the growth and carcinogenesis in endometrial cancer and are acting as a critical link between the observed increased cancer risk in patients with type II DM. Therefore, the treatment with insulin-sensitizing agents that act through reducing insulin levels, could offer a general approach to prevent the development of cancer and reduce metastasis The aim of this study was to evaluate the effect of 0.1 mM metformin dose on the proliferative and metastatic potential of endometrial cancer cells, as well as, analyze the effects of short and long-term treatment on intracellular signaling pathways related to endometrial cancer development and progression when exposed to an environment with different glucose concentrations and high insulin levels. Additionally, the endometrial three-dimensional (3D) coculture standardization to remain viable over 20 culture days. The proliferative potential was performed by using CellTitle Glo assay, and the metastatic potential was performed by using transwell migration and invasion assay. The mRNA expression of MKI67, mTOR, NOTCH1, NOTCH3 and JAG1 genes were measured by real time PCR. The cumulative population doubling rate was evaluated to determine the replication behavior of an endometrial cancer cell line throughout 20 days of treatment period. In all assays the cells were cultured in medium containing normal (5.5 mM) or high (17 mM) glucose concentration, and treated in different groups: control, insulin,metformin or combined treatment The 3D coculture model was established by using endometrial primary cells and an endometrium cancer cell line, to the model construction Matrigel® was used as an extracellular matrix. In this study, the 0.1 mM metformin dose potently inhibited the insulin action, decreasing the ability of the endometrial cancer cell line to migrate and invade in a high and normal glucose environment. On the proliferative potential this effect was not observed, however, relative cell proliferation sensitivity to metformin was observed in the range between 1 and 5 mM regardless of the present glucose concentration. In the intracellular molecular mechanisms, it was observed that the high glucose concentration creates an optimal environment for endometrial cancer cells to exhibit a more aggressive genotype and resistance to metformin during a long-term treatment. Moreover, the endometrial 3D coculture model remained viable throughout 20 culture days. Therefore, despite of endometrial cancer cells show resistance to the metformin effect when exposed to high glucose environment, the 0.1 mM metformin dose was able to inhibit the insulin action and decrease the metastatic potential of the cells, suggesting that metformin is acting clinically in combination with indirectly and direct effects could emerge as a potential agent in cancer therapy.
219

Význam ultrasonografického stanovení nepříznivých prognostických ukazatelů pro volbu adekvátní operace u zhoubného nádoru endometria / The role of untrasound assessment of adverse prognostic factors for surgical procedure tailoring in endometrial cancer patients

Frühauf, Filip January 2018 (has links)
Objectives: Preoperative ultrasound including assessment of local extent of disease in uterus, adnexal involvement and pelvic spread is recommended staging examination in patients with endometrial cancer. It is routinely based on subjective assessment by experienced sonographists. The main aim of the study was to assess if the objective methods based on simple measurements and calculations have diagnostic performance comparable to that of subjective evaluation in detection of deep myometrial invasion. Two traditional objective techniques were tested - (1) deepest invasion / normal myometrium width ratio proposed by Gordon and (2) tumor / uterine anteroposterior diameter ratio introduced by Karlsson. Methods: The prospective diagnostic accuracy study was initiated at Gynecologic Oncology Centre. All consecutive patients with histologically verified endometrial cancer undergoing transvaginal or transrectal sonography using predefined study protocol followed by surgical staging procedure were prospectively enrolled . Local staging of each endometrial tumor was subjectively evaluated by one of experienced sonographists, myometrial invasion was assessed as deep (≥ 50 %) or superficial (˂ 50 %) and cervical stromal involvement as present or absent. Concurrently, the depth of myometrial invasion was...
220

Análise de expressão gênica da via de sinalização do receptor do fator de crescimento semelhante à insulina tipo 1 no câncer de endométrio

Reis, Vania Marisia Santos Fortes dos January 2018 (has links)
O câncer de endométrio tem incidência crescente, principalmente nos países desenvolvidos, devido ao estilo de vida moderno, aumento de casos de obesidade e diabetes, e diversos outros fatores que, em conjunto, estão tornando esta neoplasia na mais comum no trato reprodutor feminino. Ele é bastante influenciado pelo estado hormonal e por fatores reprodutivos das pacientes. Assim, é mais frequente no período pós-menopausa, quando pode ocorrer um desequilíbrio na sinalização do estrogênio. A diabetes e a obesidade são causadas, principalmente, pelo excesso de triglicerídeos e glicose circulantes, e pela resistência à insulina. A hiperglicemia leva à produção excessiva de insulina e do fator de crescimento semelhante à insulina tipo 1 (IGF1), sendo que estes hormônios são considerados antiapoptóticos e promotores da proliferação celular. Sabe-se que eles agem por vias semelhantes e que, provavelmente, o mecanismo responsável pela proliferação provocada por eles está associado à via PI3K/Akt/mTOR. Desta forma, avaliamos a expressão gênica de 92 genes na rota de sinalização do IGF1R em câncer de endométrio (n=3) e endométrio normal (n=2), através da técnica de qRT-PCR (ensaio TaqMan® Array Human IGF1R Signaling). Dentro destes genes, alguns estão envolvidos diretamente com a via PI3K/Akt/MAPK, outros estão implicados em processos como proliferação, diferenciação, tumorigênese, apoptose, resposta imune, síntese proteica, entre outros. Avaliamos, também, os níveis proteicos do receptor do fator de crescimento semelhante à insulina (IGF1R), IGF1 e receptor da insulina (IR) pela técnica de imunohistoquímica, além da funcionalidade geral dos 4 genes mais diferencialmente expressos no câncer de endométrio Observamos que, dos 92 genes, 26 foram expressos somente no grupo câncer - CACNA1H, CRK, EIF2B5, ELK1, FRAP1 (MTOR), GYS1, HRAS, IGF2, IKBKB, IKBKE, ITPR3, KRAS, NFAT5, NFATC1, NFKB1, NFKBIB, NFKBIE, PIK3CA, PIK3CB, PLCB1, PLCB2, PLCG2, PRKCZ, RELB, SHC1 e YWHAZ; 46 tiveram expressão aumentada no grupo câncer de endométrio - AKT1, AKT2, ARAF, ATF4, BAD, BRAF, CACNA1C, CALM1, CALM2, CALM3, CREB1, EIF4E, FOXO3, GSK3B, IGF1, IGF1R, IKBKG, IRS1, MAP2K1, MAP2K2, MAPK3, MEF2C, MEF2D, NFATC2, NFATC3. NFKB2, NFKBIA, NRAS, PDPK1, PIK3CD, PIK3R1, PIK3R2, PLCG1, PPP3CA, PPP3R1, PRKCI, RAF1, RAPGEF1, RELA, RPS6, RPS6KB1, SOS1, YWHAB, YWHAE, YWHAH e YWHAQ, um não apresentou expressão em nenhum dos grupos (SLC2A4) e não foi possível analisar os restantes 20 genes, pois não foram expressos em todas as amostras. Quanto à expressão das proteínas IGF1R, IGF1 e IR, todas se mostraram mais expressas no câncer de endométrio e que se encontram localizadas principalmente no citoplasma das células. Assim, este trabalho mostra que a sinalização do IGF1R pode ter participação importante na aquisição do fenótipo maligno das células endometriais, e que o aumento das moléculas efetoras desta via no câncer de endométrio provavelmente está relacionado ao seu papel mitogênico. / Endometrial cancer has a growing incidence, especially in developed countries, because of the modern lifestyle, increased cases of obesity and diabetes, and several other factors that together make this disease the most common in the female reproductive tract. Endometrial cancer is strongly influenced by the hormonal state and by the reproductive factors of the patients. Thus, it is attributed to the postmenopausal period, when estrogen signaling can be unbalanced, and consequently lead to malignant proliferative patterns. Diabetes and obesity are caused mainly by the excess of circulating triglycerides and glucose, and by insulin resistance. Hyperglycemia leads to excessive production of insulin and IGF1.These hormones are considered to have antiapoptotic effects and to promote cell proliferation. It is known that they are very similar pathways, and the mechanism responsible for this proliferation is associated with the PI3K/Akt/mTOR pathway. Thus, we evaluated the expression of 92 genes in IGF1R signaling pathway in endometrial cancer (n = 3) and normal endometrium (n = 2), using qRT-PCR (TaqMan® Array Human IGF1R Signaling test). Within these genes, some are in the PI3K/Akt/MAPK pathways, others are involved in proliferation, differentiation, tumorigenesis, apoptosis, immune response, protein synthesis, among others We also evaluated the protein levels of IGF1R, IGF1 and IR by immunohistochemistry, as well as the general functionality of the 4 most differentially expressed genes in endometrial cancer. We found that 26 genes were expressed only in endometrial cancer - CACNA1H, CRK, EIF2B5, ELK1, FRAP1 (mTOR), GYS1, HRAS, IGF2, IKBKB, IKBKE, ITPR3, KRAS, NFAT5, NFATc1, NFKB1, NFKBIB, NFKBIE, PIK3CA, PIK3CB, PLCB1, PLCB2, PLCG2, PRKCZ, RELB, SHC1 and YWHAZ; 46 had increased expression in endometrial cancer, when compared to control group - AKT1, AKT2, ARAF, ATF4, BAD, BRAF, CACNA1C, CALM1, CALM2, CALM3, CREB1, eIF4E, FOXO3, GSK3B, IGF1, IGF1R IKBKG, IRS1, MAP2K1, MAP2K2, MAPK3 , MEF2C, MEF2D, NFATC2, NFATC3. NFKB2, NFKBIA, PIK3R1, PIK3R2, PLCG1, PPP3CA, PPP3R1, PRKCI, RAF1, RAPGEF1, RELA, RPS6, RPS6KB1, SOS1, YWHAB, YWHAE, YWHAH and YWHAQ, one showed no expression in neither groups (SLC2A4) and the other 20 were not expressed in all samples, so we decided not to analyze them. As for the expression of IGF1R, IGF1 and IR proteins, all them showed increased expression in endometrial cancer and were localized in the citoplasm. Thus, this work shows that IGF1R signaling may play an important role in the acquisition of a malignant phenotype by endometrial cells, and that the increase of these effectors in endometrial cancer is related to its mitogenic effects.

Page generated in 0.0558 seconds